Gail McIntyre's guest appearances

Gail McIntyre

Finding Genius Podcast

FutureTech Podcast

Naveed Akbar

Marc Guell

Laura Potterat

Jan Vijg

Paul Turner

Eleftherios Mylonakis

Cory Kidd

Charles C.J

Helius Medical Technologies

Patrick McKeown

Michael G. Surette

Katelyn Parsons

John Tucker

Jake Kushner

Erik Gunther

OwlTail

In this podcast, Gail McIntyre, Ph.D., DABT, Chief Scientific Officer of Aravive, delivers a comprehensive overview of her work as CSO developing options to treat an assortment of diseases. Before arriving at Aravive, Dr. McIntyre was a principal and/or consultant at multiple innovative pharmaceutical and biotechnology-oriented companies. Opening the podcast, Dr. McIntyre discusses in detail all the groundbreaking work they are producing at Aravive, developing treatments to stop the progression of life-threatening diseases. Dr. McIntyre explains how the Aravive system is built upon an approach to target influential signaling pathways that sustain the activation, the migration, and eventual invasion of abnormal cells into otherwise healthy tissue. The scientific officer explains how tumors work to survive in less than ideal environments. She discusses the secretion of interleukins that can affect white cells. She provides a thorough analysis of the varied processes that sometimes work to improve multiple factors for tumor growth that allows them to survive in all kinds of conditions. She talks about their current work studying the effects and impact of select oncology drugs, observing GAS6 levels in monkeys. Dr. McIntyre further explains how select particular doses of drugs can suppress GAS6 levels, specifically in regard to their ongoing study of ovarian cancer. Dr. McIntyre has authored many regulatory submissions and she is a board-certified toxicologist with noted expertise in oncology and infectious diseases, etc.

In this podcast, Gail McIntyre, Ph.D., DABT, Chief Scientific Officer of Aravive, delivers a comprehensive overview of her work as CSO developing options to treat an assortment of diseases. Before arriving at Aravive, Dr. McIntyre was a principal and/or consultant at multiple innovative pharmaceutical and biotechnology-oriented companies. Opening the podcast, Dr. McIntyre discusses in detail all the groundbreaking work they are producing at Aravive, developing treatments to stop the progression of life-threatening diseases. Dr. McIntyre explains how the Aravive system is built upon an approach to target influential signaling pathways that sustain the activation, the migration, and eventual invasion of abnormal cells into otherwise healthy tissue. The scientific officer explains how tumors work to survive in less than ideal environments. She discusses the secretion of interleukins that can affect white cells. She provides a thorough analysis of the varied processes that sometimes work to improve multiple factors for tumor growth that allows them to survive in all kinds of conditions. She talks about their current work studying the effects and impact of select oncology drugs, observing GAS6 levels in monkeys. Dr. McIntyre further explains how select particular doses of drugs can suppress GAS6 levels, specifically in regard to their ongoing study of ovarian cancer. Dr. McIntyre has authored many regulatory submissions and she is a board-certified toxicologist with noted expertise in oncology and infectious diseases, etc.

Cell Wars – Dr. Gail McIntyre, Chief Scientific Officer, Aravive – Researching Ways to Combat Disease at the Cellular Level

Gail McIntyre, Ph.D., DABT, the Chief Scientific Officer of Aravive (aravive.com), provides a thorough overview of Aravive’s important work researching and developing treatments for life-threatening diseases. Gail McIntyre has a long history of successful accomplishments in the business arena. She served as principal at IntelliDev Consulting, LLC where she assisted multiple biotechnology companies as a senior consultant. She was VP of Development for Meryx, Inc., Senior Vice President of Research at Furiex Pharmaceuticals, Inc., and was the head of Pharmaceutical Product Development, LLC’s compound partnering business for many years before arriving at Aravive where she was Senior Vice President of Research and Development prior to becoming their CSO. Dr. McIntyre talks about the innovative work they are doing at Aravive, such as developing treatments created specifically to halt the progression of life-threatening diseases, including cancer, fibrosis, and others. The Aravive system is predicated upon particular approaches to specifically target the signaling pathways that push the accelerated activation, migration, and ultimate invasion of abnormal cells into normal healthy tissues. The scientific officer explains the complex finer points of Aravive’s top products in development. The AVB-500 is their lead product candidate, an ultra-high affinity decoy protein that specifically targets the GAS6/AXL signaling pathway. The AVB-500 starves the AXL pathway of its signal by capturing the circulating and bound GAS6, which can halt the biological processes that promote and accelerate the disease. Dr. McIntyre provides an overview of how tumors fight to survive. She explains how tumors secrete interleukins, etc., that can have an impact on white cells. She details the processes that can work to enhance factors for tumor growth and advancement, allowing them to survive in less than ideal conditions. The science expert explains how they conduct studies on oncology drugs, observing GAS6 levels in monkeys. She further details how certain doses of drugs will suppress GAS6 levels in general, specifically studying ovarian cancer development.   Dr. McIntyre is the noted author of over 30 regulatory submissions and she is a board-certified toxicologist with considerable experience in many therapeutic areas such as oncology, infectious diseases, central nervous system issues, and much more.

Gail McIntyre, Ph.D., DABT, the Chief Scientific Officer of Aravive (<a href="http://aravive.com" rel="nofollow" target="_blank">aravive.com</a>), provides a thorough overview of Aravive’s important work researching and developing treatments for life-threatening diseases. Gail McIntyre has a long history of successful accomplishments in the business arena. She served as principal at IntelliDev Consulting, LLC where she assisted multiple biotechnology companies as a senior consultant. She was VP of Development for Meryx, Inc., Senior Vice President of Research at Furiex Pharmaceuticals, Inc., and was the head of Pharmaceutical Product Development, LLC’s compound partnering business for many years before arriving at Aravive where she was Senior Vice President of Research and Development prior to becoming their CSO. Dr. McIntyre talks about the innovative work they are doing at Aravive, such as developing treatments created specifically to halt the progression of life-threatening diseases, including cancer, fibrosis, and others. The Aravive system is predicated upon particular approaches to specifically target the signaling pathways that push the accelerated activation, migration, and ultimate invasion of abnormal cells into normal healthy tissues. The scientific officer explains the complex finer points of Aravive’s top products in development. The AVB-500 is their lead product candidate, an ultra-high affinity decoy protein that specifically targets the GAS6/AXL signaling pathway. The AVB-500 starves the AXL pathway of its signal by capturing the circulating and bound GAS6, which can halt the biological processes that promote and accelerate the disease. Dr. McIntyre provides an overview of how tumors fight to survive. She explains how tumors secrete interleukins, etc., that can have an impact on white cells. She details the processes that can work to enhance factors for tumor growth and advancement, allowing them to survive in less than ideal conditions. The science expert explains how they conduct studies on oncology drugs, observing GAS6 levels in monkeys. She further details how certain doses of drugs will suppress GAS6 levels in general, specifically studying ovarian cancer development.   Dr. McIntyre is the noted author of over 30 regulatory submissions and she is a board-certified toxicologist with considerable experience in many therapeutic areas such as oncology, infectious diseases, central nervous system issues, and much more.

Cellular Invasion – Gail McIntyre, PhD, DABT, Chief Scientific Officer, Aravive – Targeting the Signaling Pathways that Allow Abnormal Cells to Invade Healthy Tissue